Exicure Revenue and Competitors
Estimated Revenue & Valuation
- Exicure's estimated annual revenue is currently $11M per year.
- Exicure's estimated revenue per employee is $1,572,143
- Exicure's total funding is $105.5M.
Employee Data
- Exicure has 7 Employees.
- Exicure grew their employee count by -68% last year.
Exicure's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Accounting Officer | Reveal Email/Phone |
2 | Chief HR & Compliance Officer | Reveal Email/Phone |
Exicure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Exicure?
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNAâ„¢) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
keywords:N/A
$105.5M
Total Funding
7
Number of Employees
$11M
Revenue (est)
-68%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Exicure News
Thinking about buying stock in BioCryst Pharmaceuticals, Exicure, Uranium Energy, Paysafe, or Bilibili? InvestorsObserver (PRNewsfoto/...
Exicure, Inc. is a an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets...
Exicure (NASDAQ:XCUR) stock sinks 21% postmarket after the firm posted weak 2021 results and raised concern over its ability to continue as...
Other Companies in Skokie
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | -25% | N/A |
#2 | $0.7M | 9 | -67% | N/A |
#3 | $0.8M | 10 | 0% | N/A |
#4 | $1M | 11 | 10% | N/A |
#5 | $1.4M | 12 | N/A | N/A |